Creative Biolabs Highlights Critical Gaps in Complement Drug Screening
Gillette
•
November 16, 2026
•
Creative Biolabs highlights how C1q binding, C3b deposition, and hemolytic inhibition assays address different questions in complement drug screening, helping researchers interpret preclinical results.
Source: Gillette News Record | https://www.gillettenewsrecord.com/search/?f=rss&t=article&l=50&s=start_time&sd=desc - Read Original
Discussion (0)
Please log in to post a comment.
No comments yet. Be the first to share your thoughts!



